JP2017529326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529326A5 JP2017529326A5 JP2017507791A JP2017507791A JP2017529326A5 JP 2017529326 A5 JP2017529326 A5 JP 2017529326A5 JP 2017507791 A JP2017507791 A JP 2017507791A JP 2017507791 A JP2017507791 A JP 2017507791A JP 2017529326 A5 JP2017529326 A5 JP 2017529326A5
- Authority
- JP
- Japan
- Prior art keywords
- targeted therapeutic
- seq
- therapeutic agent
- fusion protein
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 34
- 229940124597 therapeutic agent Drugs 0.000 claims description 32
- 108020001507 fusion proteins Proteins 0.000 claims description 24
- 102000037865 fusion proteins Human genes 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 22
- 230000002132 lysosomal effect Effects 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000004988 N-glycosylation Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 229940126585 therapeutic drug Drugs 0.000 claims description 6
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 5
- 108010044965 UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase Proteins 0.000 claims description 4
- 210000003712 lysosome Anatomy 0.000 claims description 4
- 230000001868 lysosomic effect Effects 0.000 claims description 4
- 208000025820 Sanfilippo syndrome type B Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000036709 mucopolysaccharidosis type 3B Diseases 0.000 claims description 3
- 208000012227 mucopolysaccharidosis type IIIB Diseases 0.000 claims description 3
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 102100036197 Prosaposin Human genes 0.000 claims description 2
- 101710152403 Prosaposin Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036082P | 2014-08-11 | 2014-08-11 | |
| US62/036,082 | 2014-08-11 | ||
| PCT/US2015/044713 WO2016025519A1 (en) | 2014-08-11 | 2015-08-11 | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529326A JP2017529326A (ja) | 2017-10-05 |
| JP2017529326A5 true JP2017529326A5 (enExample) | 2018-09-13 |
| JP6623213B2 JP6623213B2 (ja) | 2019-12-18 |
Family
ID=54035297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507791A Active JP6623213B2 (ja) | 2014-08-11 | 2015-08-11 | リソソーム酵素に融合したマンノース−６−リン酸含有ペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10722559B2 (enExample) |
| EP (1) | EP3185889B1 (enExample) |
| JP (1) | JP6623213B2 (enExample) |
| CN (1) | CN106573039A (enExample) |
| AU (1) | AU2015301809A1 (enExample) |
| BR (1) | BR112017002741A2 (enExample) |
| CA (1) | CA2956469A1 (enExample) |
| EA (1) | EA201790178A1 (enExample) |
| MX (1) | MX2017001898A (enExample) |
| WO (1) | WO2016025519A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220133863A1 (en) * | 2010-06-25 | 2022-05-05 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| ES2896060T3 (es) | 2010-06-25 | 2022-02-23 | Shire Human Genetic Therapies | Métodos y composiciones para la administración al SNC de arilsulfatasa A |
| MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US20220023434A1 (en) * | 2018-12-19 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods |
| BR112021026866A2 (pt) * | 2019-07-02 | 2022-03-03 | M6P Therapeutics | Composições de vetor e métodos de seu uso para o tratamento de distúrbios do armazenamento lisossômico |
| CN111455004B (zh) * | 2020-02-29 | 2023-05-05 | 浙江农林大学 | 一种脂肪酶催化在线合成香豆素-3-羧酸-6’-o-d-甘露糖酯的方法 |
| WO2022026906A2 (en) * | 2020-07-30 | 2022-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Lysosomal targeting molecules comprising knottin peptides and related compositions and methods |
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス， インコーポレイテッド | Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート |
| US20250134967A1 (en) * | 2022-02-07 | 2025-05-01 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| WO2025238106A1 (en) * | 2024-05-15 | 2025-11-20 | M6P Therapeutics (Switzerland) GmbH | Lysosome-targeting degradation fusion design |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040142474A1 (en) * | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| US7560424B2 (en) * | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| ES2496493T3 (es) * | 2002-01-11 | 2014-09-19 | Bioasis Technologies Inc. | Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas |
| WO2009062195A2 (en) * | 2007-11-09 | 2009-05-14 | Anaphore, Inc. | Fusion proteins of mannose binding lectins for treatment of disease |
| ES2629853T3 (es) * | 2008-05-07 | 2017-08-16 | Biomarin Pharmaceutical Inc. | Péptidos de dirección lisosómica y usos de los mismos |
| NZ702801A (en) | 2010-06-25 | 2016-08-26 | Shire Human Genetic Therapies | Treatment of sanfilippo syndrome type b |
| EP2588130B1 (en) * | 2010-06-25 | 2016-08-17 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| US8775146B2 (en) | 2010-07-22 | 2014-07-08 | Shire Human Genetic Therapies, Inc. | Crystal structure of human alpha-N-acetylglucosaminidase |
| JP5959114B2 (ja) | 2011-05-19 | 2016-08-02 | 学校法人 明治薬科大学 | リン酸化糖鎖を含有する組換えヒトサポシンｂタンパク質及びその用途 |
| TR201802230T4 (tr) * | 2011-05-27 | 2018-03-21 | Amicus Therapeutics Inc | Lizozomal depo hastalıklarının gelişmiş tedavileri için hedefleyici peptitlerin rekombinan lizozomal enzimler üzerine kenetlenmesi için yöntemler. |
| CN103958676A (zh) | 2011-10-12 | 2014-07-30 | 辛那杰瓦生物制药股份有限公司 | 重组人naglu蛋白质及其用途 |
| LT3115372T (lt) * | 2012-11-27 | 2019-06-25 | Biomarin Pharmaceutical Inc. | Tiksliniai terapiniai lizosominio fermento sulieti baltymai ir jų panaudojimas |
-
2015
- 2015-08-11 MX MX2017001898A patent/MX2017001898A/es unknown
- 2015-08-11 EP EP15757368.4A patent/EP3185889B1/en active Active
- 2015-08-11 CN CN201580043154.1A patent/CN106573039A/zh active Pending
- 2015-08-11 AU AU2015301809A patent/AU2015301809A1/en not_active Abandoned
- 2015-08-11 WO PCT/US2015/044713 patent/WO2016025519A1/en not_active Ceased
- 2015-08-11 JP JP2017507791A patent/JP6623213B2/ja active Active
- 2015-08-11 EA EA201790178A patent/EA201790178A1/ru unknown
- 2015-08-11 BR BR112017002741-0A patent/BR112017002741A2/pt not_active Application Discontinuation
- 2015-08-11 US US15/503,223 patent/US10722559B2/en active Active
- 2015-08-11 CA CA2956469A patent/CA2956469A1/en not_active Abandoned
-
2020
- 2020-06-18 US US16/904,943 patent/US20200376095A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6881813B2 (ja) | 核酸ワクチン | |
| JP2022101618A (ja) | 条件的活性型ポリペプチド | |
| EP2559441B1 (en) | Protein complex for intracellular delivery and uses thereof | |
| JP2022095641A (ja) | 条件的活性型ポリペプチド及びそれを生成する方法 | |
| US12435121B2 (en) | Compositions and methods for stimulating natural killer cells | |
| US20190216898A1 (en) | Interleukin Combination and Use Thereof | |
| JP2016530294A (ja) | キメラポリヌクレオチド | |
| JP2015500811A5 (enExample) | ||
| ES2700149T3 (es) | Proteínas de fusión de UTI | |
| US20260048102A1 (en) | Immunomodulatory compositions and methods | |
| BR112021008832A2 (pt) | Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico | |
| CN112442129B (zh) | 肿瘤酶响应型重组焦亡蛋白递药系统及其抗肿瘤用途 | |
| F Nahhas et al. | Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics | |
| US20230137756A1 (en) | Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19 | |
| CN115433269A (zh) | 一种肿瘤抑制肽 | |
| CN101684159B (zh) | 人颗粒酶b蛋白衍生物及其在靶向治疗腺癌中的用途 | |
| JP2008502323A5 (enExample) | ||
| CN106552259A (zh) | 一种融合蛋白及其治疗疾病的用途 | |
| Avram et al. | Evaluation of the therapeutic properties of mastoparan-and sifuvirtide-derivative antimicrobial peptides using chemical structure-function relationship-in vivo and in silico approaches | |
| US20240033342A1 (en) | Compositions for treating gastrointestinal adenocarcinomas by altering the tumor microenvironment | |
| JP7863349B2 (ja) | ガンマデルタｔ細胞を刺激するための方法及び組成物 | |
| JP2022503621A (ja) | Ｔｉｍ－３系キメラタンパク質を含む併用療法 | |
| US10508139B2 (en) | Compound, use, anti-tumor pharmaceutical composition, gene construct for polypeptide expression, process for the production, process for the evaluation of tumor cells, method of sensitization of tumor cells to chemotherapeutic | |
| EA036375B1 (ru) | Tal-эффекторная нуклеаза для целевого нокаута вич-корецептора ccr5 | |
| CN120173884A (zh) | 功能优化的嵌合抗原受体效应细胞及其在制备治疗急性髓系白血病的组合物中的应用 |